QURE News

uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

QURE INVESTOR ALERT: Contact Kirby McInerney LLP About Securities Class Action Lawsuit On Behalf of uniQure N.V. Investors

Pomerantz LLP Informs Shareholders of Securities Class Action Against uniQure N.V. – QURE

uniQure N.V. (QURE) Class Action Lawsuit Filed by Kessler Topaz Meltzer & Check, LLP: Investors Face April 13, 2026, Deadline

QURE ALERT: FDA Reportedly Accuses uniQure of Pushing “Distorted” and “Manipulated” Data For “Failed” AMT-130 Drug Amid Pending Securities Class Action – Hagens Berman

QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall Law Firm

QURE DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds uniQure (QURE) Investors of Securities Class Action Deadline on April 13, 2026

QURE Shareholder Alert: April 13, 2026 Lead Plaintiff Deadline in uniQure N.V. Securities Class Action Lawsuit — The Gross Law Firm

QURE INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that uniQure N.V. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit!

Pomerantz LLP Issues Reminder to Shareholders in uniQure N.V. of Class Action Lawsuit – QURE